Navigation Links
Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone
Date:1/6/2014

ls.gov/ct2/show/NCT01897571.

Epizyme granted Eisai a worldwide license to EPZ-6438 (Eisai refers to this therapeutic candidate as E7438), subject to Epizyme's right to opt in for co-development, co-commercialization and profit share arrangement with Eisai in the United States. Epizyme is working with Roche and Eisai to develop a companion diagnostic to identify patients with EZH2 point mutations. Additional information about these partnerships may be found here: http://www.epizyme.com/about-us/partnerships/.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, expectations regarding the Company's cash balance and future expectations and plans and prospects for the Company and other statements containi
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Epizyme, Inc. to Be Added to NASDAQ Biotechnology Index (NBI) and NASDAQ Global Select Market
2. Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
3. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
4. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
5. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
6. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
7. Advanced Biofuels USA's Joanne Ivancic Recognized as One of Top 100 People in the BioEconomy by Biofuels Digest
8. Westchase Neck Injury Chiropractor is Now Offering the Newest Advanced Care Treatments for Injury and Chronic Pain, Courtesy of Elan Wellness Center
9. ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS
10. New Ocean Sensing and Monitoring Brings Tutorial Approach to Latest Advances
11. Phoenix Research Labs Partners with Voxeleron to Advance Technology for Eye Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... increasing global demand for health ... economics and market access support, BOSTON, Oct. ... Adam Barak as Vice President., Mr. Barak brings 16 ... pricing and reimbursement strategies,for drugs, medical devices, and diagnostics in ...
... Also Announces Completion of Enrollment in U.S. Phase ... Hepatitis C,Genotype 1, TAMPA, Fla., Oct. 28 ... announced the presentation of studies,of nitazoxanide at the ... the Study of Liver Diseases (AASLD), also known ...
... - Laureate To Manufacture Tolera,s Monoclonal Antibody ... 28 Laureate Pharma, Inc., a,full-service biopharmaceutical ... it has entered into a cGMP contract ... company that,develops and offers targeted therapies and ...
Cached Biology Technology:Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability 2Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc. 2
(Date:4/20/2014)... for both basic researchers and medical practitioners, researchers ... Maryland have developed a new computational method that ... RNA sequencing (RNA-seq) data., With the new method, ... of gene expression that previously took many hours ... accuracy that equals or exceeds previous methods. The ...
(Date:4/18/2014)... A survey of emergency contraceptive pills in Peru ... were either of substandard quality or falsified. Many ... had the wrong active ingredient. One batch had ... detect the fake drugs, researchers at the Georgia ... mass spectrometry to quickly assess suspected counterfeit drugs ...
(Date:4/18/2014)... as they,re planted may be good news for a garden. ... wild, a plant whose seeds sprouted at the first ,warm ... an insurance policy against late frosts or unexpected dry spells, ... Plants whose seeds put off sprouting until conditions are ... team of researchers working at the National Evolutionary Synthesis Center ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Plants with dormant seeds give rise to more species 2
... belonging to the genus Daphniola was found by a ... spring covered by snow on Mt. Parnassos, central Greece. This study ... . The new species, Daphniola eptalophos , ... a black penis with a small colorless outgrowth on the left ...
... Acinetobacter baumannii (MDR-AB) was found in the ... colonized or infected with the pathogen, according to a ... American Journal of Infection Control , the official ... Infection Control and Epidemiology. The study examined ...
... of Southern California (USC) professor Mary Ann Pentz, Ph.D., shows ... are more likely to drink alcohol in high school than ... September-October 2011 issue of the journal Alcohol and Alcoholism ... that may benefit from special prevention programs. "As you ...
Cached Biology News:Acinetobacter baumannii found growing in nearly half of infected patient rooms 2Underage drinking among close friends high indicator of future alcohol use by black teens 2
Recombinant Rhesus Monkey IFN-Alpha...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
Biology Products: